drug resistance – Page 6

Synergistic Effects of Cold Atmospheric Multiple Plasma Jet and Amphotericin B on Leishmania major: An In-Vitro Study

mycolabadmin

Researchers tested a new cold plasma technology combined with an existing anti-parasite drug (amphotericin B) against Leishmania parasites that cause skin infections. The cold plasma, which contains reactive chemicals, killed the parasites by triggering their programmed cell death (apoptosis) while causing minimal harm to human immune cells. When combined with the medication, the treatment was even more effective, potentially allowing lower drug doses with fewer side effects.

Superficial Fungal Infections in Children—What Do We Know?

mycolabadmin

Fungal infections of the skin, hair, and nails are increasingly common in children worldwide, especially in warm, humid climates and in crowded living conditions. These infections are caused by germs that live on the skin and can spread through contact with infected people or animals. Children are particularly vulnerable due to their developing immune systems, but most infections are treatable with topical creams or oral medications, with terbinafine being the most effective option currently available.

Extensive erythematous plaques of fungal origin in an overseas student: Cutaneous manifestation of coccidioidomycosis

mycolabadmin

A 21-year-old student studying in Arizona developed unusual skin rashes months after returning to China. Doctors had difficulty diagnosing the condition because it lacked typical symptoms of the fungal infection coccidioidomycosis. By using multiple diagnostic methods including DNA sequencing and fungal culture, they identified the infection as caused by Coccidioides posadasii. When the initial antifungal drug didn’t work, testing showed the fungus was resistant, so they switched to a different antifungal called voriconazole, which successfully cured the infection after 12 months.

Fungal Δ9-fatty acid desaturase: a unique enzyme at the core of lipid metabolism in Aspergillus fumigatus and a promising target for the search for antifungal strategies

mycolabadmin

Certain dangerous fungal infections like aspergillosis are difficult to treat because current antifungal drugs have significant side effects or the fungi are developing resistance. Scientists have discovered that a specific enzyme called Δ9-fatty acid desaturase, which fungi need to make fats for their cell membranes, has a unique structure different from human cells. This structural difference offers a new opportunity to design antifungal drugs that could kill fungi without harming human cells, potentially providing safer and more effective treatments for serious fungal infections.

First report of infections due to Candidozyma (formerly Candida) auris in Botswana, 2022–2024

mycolabadmin

Researchers in Botswana discovered the first documented cases of a dangerous fungal infection called Candidozyma auris in their country. This yeast was found in 10 patients at a major hospital, mostly in intensive care units, between 2022 and 2024. The fungus was resistant to common antifungal drugs like fluconazole but could still be treated with other medications. The findings highlight how this emerging pathogen is spreading across Africa and stress the importance of improved laboratory testing and disease monitoring in developing countries.

Breaking down biofilms across critical priority fungal pathogens: proteomics and computational innovation for mechanistic insights and new target discovery

mycolabadmin

Fungal infections like cryptococcal meningitis and invasive aspergillosis are becoming increasingly difficult to treat because fungi form protective structures called biofilms that resist our current medications. Researchers are using advanced techniques like mass spectrometry to identify the proteins that help fungi build these biofilms, combined with artificial intelligence tools to design new drugs that could break down these protective shields. This combined approach offers hope for developing better antifungal treatments that could save millions of lives.

Anti-Influenza Activity of Medicinal Material Extracts from Qinghai–Tibet Plateau

mycolabadmin

Researchers tested extracts from traditional Tibetan medicinal plants, mushrooms, and lichens to see if they could fight influenza virus. They found that seven out of nine extracts could reduce influenza virus infection in laboratory cells, with a mushroom extract called Armillaria luteo-virens showing particularly strong antiviral effects. These results suggest that traditional medicinal materials from the Qinghai–Tibetan plateau could be valuable sources for developing new flu treatments that might work better against drug-resistant flu strains.

Moving beyond multi-triazole to multi-fungicide resistance: Broader selection of drug resistance in the human fungal pathogen Aspergillus fumigatus

mycolabadmin

Aspergillus fumigatus is a dangerous fungal infection treated with triazole drugs, but the fungus is developing resistance to multiple antifungal medications. This resistance appears to be selected in agricultural settings where fungicides are used on crops, and resistant strains then spread to humans through the air. The problem is worse because agricultural fungicides are selecting for strains resistant to multiple drug classes at once, making infections harder to treat. Addressing this issue requires reducing fungicide use in agriculture and better strategies for managing antifungal resistance.

New approaches to tackle a rising problem: Large-scale methods to study antifungal resistance

mycolabadmin

Fungal infections are becoming increasingly resistant to antifungal drugs, creating a serious public health challenge. Scientists are using advanced genetic sequencing and laboratory techniques to understand how fungi develop drug resistance and identify the specific genetic changes responsible. By cataloging resistance mutations and creating shared databases, researchers aim to develop better diagnostic tests and treatment strategies to combat these dangerous infections.

Bioactivity and chemical screening of endophytic fungi associated with seaweeds Gracilaria sp. and Sargassum sp. of the Bay of Bengal, Bangladesh

mycolabadmin

Researchers discovered several types of fungi living inside seaweed from Bangladesh’s Bay of Bengal coast. These fungi produce natural compounds that can fight bacteria, reduce harmful oxidative damage, and potentially kill cancer cells. The study identified specific chemical compounds responsible for these beneficial properties, suggesting these fungi could be useful sources for developing new medicines.

Research Keyword: drug resistance